Proteostasis files $86M IPO; Novartis publishes Cosentyx studies;

> Cambridge, MA-based Proteostasis Therapeutcs filed for an $86 million IPO. Filing

> Results of the MEASURE 1 and MEASURE 2 Phase III studies for Novartis's Cosentyx (secukinumab) in ankylosing spondylitis were published in The New England Journal of Medicine. Release

Suggested Articles

The financing sets AM-Pharma up to advance in sepsis-associated acute kidney injury independently now Pfizer has turned down its option to buy.

The FDA sent Eton's partner, Bausch Health, a complete response letter that raised “no concerns” about the clinical data in the drug’s application.

A new partnership will test drug cocktails containing Karyopharm's new product Xpovio in cell samples from glioblastoma patients.